<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777591</url>
  </required_header>
  <id_info>
    <org_study_id>HSR210033</org_study_id>
    <nct_id>NCT04777591</nct_id>
  </id_info>
  <brief_title>Effectiveness of Exparel TAP Block in Breast Free Flap Reconstruction</brief_title>
  <official_title>Effectiveness of Exparel TAP Block in Breast Free Flap Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transversus Abdominis Plane (TAP) block is a useful tool in pain management after abdominal&#xD;
      surgery. It is a regional nerve block that targets T6-L1 thoracolumbar nerves running in the&#xD;
      plane between internal oblique and transversus abdominis muscle. It is shown to help with&#xD;
      post-operative pain management, reducing pain scores and narcotic pain medication use, as&#xD;
      well as promoting earlier return to activity and recovery. TAP block became a very popular,&#xD;
      safe, and effective therapeutic adjunct for many different abdominal surgeries ranging from&#xD;
      obstetric procedures to general surgery procedures like colorectal surgery. Furthermore, it&#xD;
      is used in plastic surgery procedures such as Deep Inferior Epigastric Perforator (DIEP) free&#xD;
      flap or Transverse Rectus Abdominis Myocutaneous (TRAM) flap, as they involve extensive&#xD;
      amount of abdominal soft tissue incision. Previous studies have shown that TAP block in these&#xD;
      procedures significantly reduce post-op pain and narcotic pain medication use. More recently,&#xD;
      Exparel (liposomal bupivacaine) has risen to spotlight for providing a longer, sustained&#xD;
      local anesthesia. Various surgical disciplines have adopted this agent as part of their pain&#xD;
      management protocol. However, there are no literatures that describe the effect of TAP block&#xD;
      using Exparel for breast free flap population. The study hypothesize that delivering TAP&#xD;
      block with Exparel (vs. plain bupivacaine) will provide longer regional blocking effect,&#xD;
      hence aiding in pain control and recovery postoperatively. The investigators will be&#xD;
      analyzing postop narcotic pain medication requirement and pain scores to look into this&#xD;
      question.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control group: TAP block with plain bupivacaine Intervention group: TAP block with plain bupivacaine + liposomal bupivacaine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post-op pain scores during initial hospitalization</measure>
    <time_frame>During initial hospitalization following surgery up to Day 5 (or to the point of discharge), whichever came first</time_frame>
    <description>Visual analog pain scale (0-10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post-op narcotic pain medication use during hospitalization</measure>
    <time_frame>during initial hospitalization following surgery up to Day 5 (or to the point of discharge), whichever came first</time_frame>
    <description>total amount of morphine milliequivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post-op narcotic pain medication use after discharge (within 30 days of discharge)</measure>
    <time_frame>from the time of discharge to 30 days post discharge</time_frame>
    <description>total amount of morphine milliequivalent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>during initial hospitalization following surgery up to Day 5 (or to the point of discharge), whichever came first</time_frame>
    <description>hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post-op nausea and vomiting (PONV)</measure>
    <time_frame>during initial hospitalization following surgery up to Day 5 (or to the point of discharge), whichever came first</time_frame>
    <description>Incidence of PONV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Breast Reconstruction</condition>
  <arm_group>
    <arm_group_label>Control - plain bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receives plain bupivacaine TAP block as part of multi-modal pain control intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental - Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives plain bupivacaine + liposomal bupivacaine TAP block as part of multi-modal pain control intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine TAP block</intervention_name>
    <description>Group will receive Liposomal bupivacaine TAP block (mixed with plain bupivacaine) intraoperatively during free flap breast reconstruction as part of the multimodal pain control.</description>
    <arm_group_label>Experimental - Liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacain</intervention_name>
    <description>Group will receive plain bupivacaine TAP block intraoperatively during free flap breast reconstruction as part of the multimodal pain control.</description>
    <arm_group_label>Control - plain bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All female patients who are 18 years or older who will undergo unilateral or bilateral&#xD;
             abdomen-based free flap breast reconstruction at UVA Medical Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with ages &lt;18 years&#xD;
&#xD;
               -  Allergy to local anesthetic&#xD;
&#xD;
               -  Inability to tolerate standard postoperative pain management regimen (Tylenol,&#xD;
                  Toradol, and Oxycodone PRN) for any reason&#xD;
&#xD;
               -  Subjects who cannot read or understand English&#xD;
&#xD;
               -  Subjects who are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Stranix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel H Park, MD</last_name>
    <phone>5714287278</phone>
    <email>rhp7gu@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>John Stranix</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>TAP block</keyword>
  <keyword>Regional block</keyword>
  <keyword>ERAS</keyword>
  <keyword>liposomal bupivacaine</keyword>
  <keyword>free flap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

